Your browser doesn't support javascript.
loading
Effect of probiotics during vonoprazan-containing triple therapy on gut microbiota in Helicobacter pylori infection: A randomized controlled trial.
Kakiuchi, Toshihiko; Mizoe, Akihiko; Yamamoto, Kentaroh; Imamura, Ichiro; Hashiguchi, Kazutoshi; Kawakubo, Hiroharu; Yamaguchi, Daisuke; Fujioka, Yasuhiko; Nakayama, Aiko; Okuda, Masumi; Matsuo, Muneaki.
Afiliación
  • Kakiuchi T; Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan.
  • Mizoe A; Department of Gastroenterology, Kahan Hospital, Karatsu, Japan.
  • Yamamoto K; Department of Gastroenterology, Yamamoto Memorial Hospital, Imari, Japan.
  • Imamura I; Department of Gastroenterology, Imamura Hospital, Tosu, Japan.
  • Hashiguchi K; Department of Gastroenterology, Imamura Hospital, Tosu, Japan.
  • Kawakubo H; Department of Gastroenterology, ImariArita Kyoritsu Hospital, Nishimatsuura, Japan.
  • Yamaguchi D; Department of Gastroenterology, Ureshino Medical Center, Ureshino, Japan.
  • Fujioka Y; Department of Gastroenterology, Fujioka Hospital, Saga, Japan.
  • Nakayama A; Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan.
  • Okuda M; Department of Pediatrics, Hyogo College of Medicine, Nishinomiya, Japan.
  • Matsuo M; Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan.
Helicobacter ; 25(3): e12690, 2020 Jun.
Article en En | MEDLINE | ID: mdl-32207209
BACKGROUND: Probiotics are beneficial to patients with Helicobacter pylori infections by modulating the gut microbiota. Biofermin-R (BFR) is a multiple antibiotic-resistant lactic acid bacteria preparation of Enterococcus faecium 129 BIO 3B-R and is effective in normalizing the gut microbiota when used in combination with antibiotics. This study aimed to determine the effect of BFR in combination with vonoprazan (VPZ)-based therapy on gut microbiota. METHODS: Patients with positive urinary anti-H pylori antibody test (primary test) and fecal H pylori antigen test (secondary test) were examined. Patients in group 1 (BFR- ) received VPZ (20 mg twice daily), amoxicillin (750 mg twice daily), and clarithromycin (400 mg twice daily) for 7 days. Patients in group 2 (BFR+ ) received BFR (3 tablets/day) for 7 days, in addition to the aforementioned treatments. Following treatment, the relative abundance, α-diversity, and ß-diversity of gut microbiota were assessed. RESULTS: Supplementation with BFR prevented the decrease in a-diversity after eradication therapy (Day 7). ß-diversity was similar between groups. The incidence rate of diarrhea was non-significantly higher in the BFR- than in the BFR+ group (73.1% vs 56.5%; P = .361). Stool consistency was comparable in the BFR+ group on Days 7 and 1 (3.86 ± 0.95 vs 3.86 ± 1.46; P = .415). CONCLUSION: Biofermin-R combined with VPZ-based therapy resulted in higher microbial α-strain diversity and suppressed stool softening during H pylori eradication therapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirroles / Sulfonamidas / Helicobacter pylori / Infecciones por Helicobacter / Probióticos / Microbioma Gastrointestinal Tipo de estudio: Clinical_trials Límite: Adolescent / Female / Humans / Male Idioma: En Revista: Helicobacter Asunto de la revista: BACTERIOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirroles / Sulfonamidas / Helicobacter pylori / Infecciones por Helicobacter / Probióticos / Microbioma Gastrointestinal Tipo de estudio: Clinical_trials Límite: Adolescent / Female / Humans / Male Idioma: En Revista: Helicobacter Asunto de la revista: BACTERIOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido